Treatment with Obecabtagene Autoleucel Results in Durable Response Among Adults with Relapsed or Refractory B-Cell ALL By Ogkologos - December 12, 2024 869 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the FELIX study Source RELATED ARTICLESMORE FROM AUTHOR ESMO Announces 2026 Society Award Recipients Honouring Excellence in Cancer Research, Care and Leadership Adjuvant Olaparib Continues to Improve Multiple Outcomes in Patients with Germline BRCA1/2-associated High-Risk HER2-negative EBC EMA Recommends Refusing the Marketing Authorisation for Copper (64Cu) Oxodotreotide MOST POPULAR Trialling a new way to boost CAR T-cell therapy June 23, 2021 Building Your Fort of Support: Tips from a Breast Cancer Social... October 27, 2021 With Longer Follow-Up, Trastuzumab Deruxtecan Continues to Demonstrate Superior Efficacy Over... June 27, 2024 EMA Recommends Extension of Indications for Tislelizumab to First-Line Treatment of... November 19, 2024 Load more HOT NEWS FDA Approves Lisocabtagene Maraleucel for Relapsed or Refractory Mantle Cell Lymphoma Belzutifan Approved to Treat Tumors Linked to Inherited Disorder VHL FDA Expands Early Breast Cancer Indication for Abemaciclib with Endocrine Therapy Accepting Help During Cancer Is Hard, But It Can Benefit You...
